205 related articles for article (PubMed ID: 35448172)
21. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
22. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
23. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
25. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
Ahnström M; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
Breast Cancer Res Treat; 2005 May; 91(2):145-51. PubMed ID: 15868442
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic and Predictive Factors for Pancreatic Adenocarcinoma].
Karásek P; Hermanová M
Klin Onkol; 2016; 29(5):336-341. PubMed ID: 27739311
[TBL] [Abstract][Full Text] [Related]
27. Cyclin D1 and bax influence the prognosis after pancreatoduodenectomy for periampullary adenocarcinoma.
Tomazic A; Pegan V; Ferlan-Marolt K; Pleskovic A; Luzar B
Hepatogastroenterology; 2004; 51(60):1832-7. PubMed ID: 15532837
[TBL] [Abstract][Full Text] [Related]
28. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
[TBL] [Abstract][Full Text] [Related]
29. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
30. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.
Pandey V; Storz P
Expert Rev Anticancer Ther; 2019 Jun; 19(6):473-482. PubMed ID: 31148495
[No Abstract] [Full Text] [Related]
31. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
32. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
[TBL] [Abstract][Full Text] [Related]
33. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
34. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
[TBL] [Abstract][Full Text] [Related]
35. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
37. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
39. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
Kirchner M; Kluck K; Brandt R; Volckmar AL; Penzel R; Kazdal D; Endris V; Neumann O; Seker-Cin H; Goldschmid H; Glade J; Allgäuer M; Kriegsmann M; Winter H; Muley T; Perner S; Frost N; Reck M; Fröhling S; Schirmacher P; Thomas M; Budczies J; Christopoulos P; Stenzinger A
ESMO Open; 2021 Oct; 6(5):100253. PubMed ID: 34487971
[TBL] [Abstract][Full Text] [Related]
40. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]